Deep B-cell receptor repertoire analysis for your most complex autoimmune, Long COVID, and post-viral patients. From a standard blood draw to an actionable clinical report — results in 2–3 weeks.
Workflow
Place an order through our portal. We ship a collection kit to your clinic or patient's home.
Standard blood draw (10 mL EDTA tube). Pre-paid return shipping included in the kit.
BCR heavy chain sequencing + AI-powered repertoire profiling at our CLIA-compliant partner lab.
Structured report delivered via secure portal within 2–3 weeks. Clinician-facing, actionable format.
Sample Report
A structured, clinician-facing report designed to inform treatment decisions — not a raw data dump.
Important
Clono supplements standard autoimmune workup. It does not replace ANA, anti-dsDNA, or disease-specific antibody panels — it reveals immune dynamics those tests cannot detect. Use Clono alongside, not instead of, established diagnostic workflows.
Clinical Scenarios
Patient presents with persistent fatigue, POTS, and cognitive dysfunction 14 months post-infection. Standard workup unremarkable.
BCR profiling reveals expanded IgG1 clones with anti-autonomic receptor and anti-ganglioside signature matches.
Supports trial of IVIG or low-dose rituximab targeting pathogenic B-cell clones.
Inflammatory arthritis with negative RF, anti-CCP, and ANA. Empiric DMARD therapy underway.
High clonal expansion with IGHV4-34-enriched repertoire and elevated SHM — consistent with B-cell-driven mechanism despite seronegativity.
Rationale for adding B-cell-targeted therapy. Baseline for monitoring treatment response.
Lupus patient eligible for either belimumab or rituximab. Both approved, no clear selection criteria.
Low B-cell activity score suggests disease maintained by long-lived plasma cells, not active B-cell clones.
Anti-BAFF (belimumab) may be more appropriate than anti-CD20. Avoids non-response to rituximab.
Early Access
We're onboarding clinicians for early access. Receive a sample report and priority ordering when we launch.